Exceptional Response of BRAFV600E-Mutated Acinar Cell CUP to BRAF/MEK Inhibition

Research output: Contribution to journal › Research article › Contributed

Contributors

  • Irina A Kerle - , National Center for Tumor Diseases Dresden, National Center for Tumor Diseases (NCT) Dresden, German Cancer Consortium (DKTK) Partner Site Dresden (Author)
  • Anne-Marie Scheuble - , University Hospital Leipzig (Author)
  • Benjamin Kobitzsch - , University Hospital Leipzig (Author)
  • Gertraud Stocker - , University Hospital Leipzig (Author)
  • G G Ruth Hiller - , University Hospital Leipzig (Author)
  • Maja Badendick - , University Hospital Leipzig (Author)
  • Doreen William - , Institute of Clinical Genetics, National Center for Tumor Diseases Dresden, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK) Partner Site Dresden (Author)
  • Alexander Krueger - , Dresden Neurovascular Center (Author)
  • Thomas Gross - , Dresden Neurovascular Center (Author)
  • Anja Koegler - , German Cancer Consortium (DKTK) Partner Site Dresden, National Center for Tumor Diseases (NCT) Dresden, German Cancer Research Center (DKFZ), Dresden Neurovascular Center (Author)
  • Andreas Hartig - , Institute of Pathology, University Hospital Carl Gustav Carus Dresden (Author)
  • Daniela Richter - , German Cancer Research Center (DKFZ) (Author)
  • Daniela E Aust - , Institute of Pathology, University Hospital Carl Gustav Carus Dresden (Author)
  • Evelin Schroeck - , Institute of Clinical Genetics, National Center for Tumor Diseases Dresden, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK) Partner Site Dresden (Author)
  • Christoph Heining - , National Center for Tumor Diseases Dresden, German Cancer Consortium (DKTK) Partner Site Dresden (Author)
  • Hanno Glimm - , National Center for Tumor Diseases Dresden, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK) Partner Site Dresden (Author)
  • Ulrich T Hacker - , University Hospital Leipzig (Author)

Abstract

Complete remission of BRAF V600E-driven ACC CUP by BRAF/MEK inhibition underscores importance of precision oncology.

Details

Original languageEnglish
Article numbere2400030
JournalJCO precision oncology
Volume8
Issue number8
Publication statusPublished - May 2024
Peer-reviewedNo

External IDs

Mendeley 138e238f-0d9a-357b-aaf1-6af2a3aaec97
Scopus 85200466648
ORCID /0009-0003-2782-8190/work/198593656

Keywords

Keywords

  • Proto-Oncogene Proteins B-raf/genetics, Humans, Protein Kinase Inhibitors/therapeutic use, Mutation, Male, Female, Middle Aged, Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors